Please assess the completion status of the following clinical trial:

Trial Title: A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women.~* Negative pregnancy test.~* Adequate contraception during the study period and for 1 month following study completion.~* Overt or relative iron deficiency at screening defined as follows:~Serum ferritin \<50 ng/mL AND transferrin saturation \<20%, OR Serum ferritin \<30 ng/mL.~- Serum C-reactive protein: \<5 mg/L if not on oral contraception, OR \<20 mg/L if use of oral contraception~* Intolerance to oral iron formulations, or lack of efficacy of oral iron formulations.~* Minimum total score of 5 on the Visual analogic scale of fatigue.~* Normal levels of vitamin B12 and folic acid at screening.~* Availability and willingness to complete all study visits and procedures per protocol.~* Ability to sign an informed consent.~Exclusion Criteria:~* Age \<18 years.~* Menopause (defined as an amenorrhea of at least 12 months).~* Irregularly menstruating women (menstrual cycle outside a range of 24-38 days in duration) or experiencing overt metrorrhagia (simple spotting not being an exclusion criteria).~* Body mass index \<18.5 kg/m2 or \>30 kg/m2.~* Diabetes, defined as subjects with HbA1c ≥ 6.5 % and/or with fasting blood glucose levels ≥ 7 mmol/l and/or with a history of diabetes and/or by the use of anti-diabetic drugs.~* Hb level \<117 g/L or known haemoglobinopathy or haemochromatosis.~* Blood transfusion within the last 12 weeks.~* Intake of iron preparations 4 weeks prior to screening.~* Known hypersensitivity to FCM or to any other iron preparation.~* Suspicion of major depressive disorder based on Patient Health Questionnaire.~* Known chronic inflammatory disease, including human immunodeficiency virus, hepatitis B or hepatitis C virus infection.~* Active malignancy.~* Decreased renal function (estimated glomerular filtration rate using the CKD-EPI equation\<60 ml/min/1.73m2).~* Liver dysfunction (aspartate aminotransferase and alanine aminotransferase \> 3-fold upper limit).~* Angina (Class IV).~* Asthma.~* Documented sleep apnoea.~* Important recent weight loss (\>10% within the past month).~* Thyroid dysfunction (thyroid stimulating hormone \>4 µU/mL).~* Reported weekly alcohol consumption \> 14 standard drinks.~* Drug abuse (any drug consumption reported in the past 12 months).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric carboxymaltose arm (Type: ACTIVE_COMPARATOR): Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
- Placebo arm (Type: PLACEBO_COMPARATOR): A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).